Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by IGC Pharma, Inc.
IGC Pharma Reports First Quarter Fiscal 2025 Results
August 08, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
July 18, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
July 09, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
June 25, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
June 24, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
June 18, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
June 10, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
April 16, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Adds Advisor in Artificial Intelligence
April 09, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
March 20, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
March 20, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
March 12, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
February 28, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
February 23, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Reports Third Quarter Fiscal 2024 Results
February 16, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
February 01, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
January 23, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial
January 17, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s
December 19, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
December 13, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
December 06, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
November 21, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Reports Second Quarter Fiscal 2024 Results
November 13, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
October 19, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Announces Results of its 2023 Annual Stockholders Meeting
August 21, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials
August 14, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico
August 02, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference
July 18, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Reports Financial Results for Fiscal Year Ended March 31, 2023
July 12, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research
July 07, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.